Key Highlights

● Moderna rallied sharply ahead of joining the Nasdaq-100 on Oct. 9, replacing Warner Bros. Discovery.

● Investors are also positioning ahead of Phase 3 cancer-vaccine data due at ESMO on Oct. 24.

● The gain stood out against a weak health care sector, where Merck and Bristol-Myers Squibb both fell.

Moderna climbed sharply on Monday, Oct. 5, as investors positioned for its entry into the Nasdaq-100 later this week and for key cancer-vaccine data due later this month.

Index entry brings a wave of buyers

Moderna (NASDAQ:MRNA) rallied on Monday, finishing among the strongest stocks in the S&P 500. Reports differed slightly on the exact size of the gain, but every account had the stock sharply higher.

The clearest driver is index-related. Moderna joins the Nasdaq-100 effective Oct. 9, replacing Warner Bros. Discovery, a change announced on Oct. 2. When a company enters a major index, funds that track that index have to buy its shares, and that expected Demand often lifts the stock in the days before the switch.

A big year for the Vaccine maker

Monday's rise added to a remarkable run. Moderna shares have soared since the start of the year, making it one of the standout large-cap performers of 2026.

Investors are also watching intismeran, a personalized cancer vaccine Moderna is developing with Merck (NYSE:MRK). Phase 3 data from the INTerpath-001 study is due to be presented at the ESMO medical conference on Oct. 24, and investors are positioning ahead of that readout.

Moderna is best known for its messenger RNA technology, which teaches cells to produce proteins that trigger an immune response. The same approach underpins its cancer-vaccine work.

Vaccines in focus across the market

Vaccine stocks drew attention all day. Vaxcyte (NASDAQ:PCVX) soared after its VAX-31 pneumococcal vaccine met all of its main goals in a pivotal Phase 3 trial against shots from Pfizer (NYSE:PFE) and Merck. Novavax (NASDAQ:NVAX) and Emergent BioSolutions (NYSE:EBS) also jumped on reports of a suspected plague case at a Russian research institute, a case that remains unconfirmed and has been described as pneumonia of unknown cause.

Moderna's gain stood out against a weak backdrop for big health care names. The sector was the softest in the S&P 500 at midday. Merck was the worst stock in the Dow, and Bristol-Myers Squibb (NYSE:BMY) slid after a Leerink Partners downgrade.

Records for the Nasdaq

The broader market was firm. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 also set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90.

Rates remain a worry. The 10-year Treasury Yield rose to its highest close since 2002, and the ISM services survey showed prices paid at the highest since July 2022. Still, Friday's weak jobs report, with only 29,000 positions added in September, cut the odds of another Fed hike in October to roughly one in four or less.

Daniela Hathorn of Capital.com said: "Equities are benefiting from Friday's softer US labor market report which saw September payrolls increase by just 29,000."

Oil helped too. Brent settled at $100.32 a barrel and US crude near $89.43, both lower on the day, after G7 nations agreed to release 100 million barrels of crude and diesel from emergency reserves.

What to watch

Moderna's Nasdaq-100 inclusion takes effect on Oct. 9, so trading around that date could stay active as Index Funds adjust. The bigger company-specific event is Oct. 24, when the INTerpath-001 Phase 3 data on intismeran are set to be presented at ESMO.

On the macro calendar, the Fed releases minutes of its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday, Delta Air Lines Friday, and bank Earnings begin on Oct. 13 ahead of the Fed's Oct. 27–28 meeting.